Emoxypine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Emoxypine
2-Ethyl-6-methyl-3-hydroxypyridine.svg
Emoxypine ball-and-stick.png
Systematic (IUPAC) name
2-Ethyl-6-methyl-3-hydroxypyridine
Clinical data
Trade names Mexidol
Legal status Legal
Routes Oral & IV
Identifiers
CAS number 2364-75-2
ATC code None
PubChem CID 114681
ChemSpider 102688 YesY
Synonyms Emoxipine, Emoxypin, Epigid, 6-Methyl-2-ethyl-3-hydroxypyridine
Chemical data
Formula C8H11NO 
Mol. mass 137.179 g/mol
Physical data
Melt. point 170–172 °C (338–342 °F) [1]
 YesY (what is this?)  (verify)

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine), also known as Mexidol or Mexifin when used as the succinate salt, is an antioxidant manufactured in Russia by Pharmasoft Pharmaceuticals.[2] Its chemical structure resembles that of pyridoxine (a type of vitamin B6). It is not approved for any medical use in the United States or Europe.

History[edit]

Emoxypine was first synthesized by L.D. Smirnov and K.M. Dumayev, then studied and developed in the Institute of Pharmacology, Russian Academy of Medical Sciences and National Scientific Center of Bioactive Substances Safety.[3]

Use[edit]

In Russia, emoxypine has a wide range of applications in medical practice. It purportedly exercises anxiolytic, anti-stress, anti-alcohol, anticonvulsant, nootropic, neuroprotective and anti-inflammatory action.[citation needed] Emoxypine presumably improves cerebral blood circulation, inhibits thrombocyte aggregation, lowers cholesterol levels, has cardioprotective and antiatherosclerotic action.[3][medical citation needed]

Mechanism of action[edit]

Emoxypine's mechanism of action is believed to be its antioxidant and membrane-protective effects with the following key components:[3][4][medical citation needed]

Clinical study[edit]

One study determined the effectiveness of emoxypine in 205 patients with clinical manifestations of lumbosacral radiculopathy (LSR). Patients were divided into two groups, and further were divided into subgroups depending on the presence of motor disturbances. All patients received a course of conventional medical treatment and physiotherapy; main group additionally received emoxypine. Thereafter, clinical-neurological control of long-term results of treatment in subgroups of patients was performed. The results showed that the use of emoxypine in the combined therapy of patients with LSR lead to significant and persistent reduction of severity of pain syndrome and rapid recovery of function of spinal roots and peripheral nerves compared with conventional therapy.[3][5]

References[edit]

  1. ^ W. Gruber (1953). "SYNTHESIS OF 3-HYDROXY-2-ALKYLPYRIDINES". Canadian Journal of Chemistry 31 (6): 564–568. doi:10.1139/v53-079.  edit
  2. ^ mexidol.ru, Pharmasoft Website
  3. ^ a b c d e Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia http://www.mexidol.ru/en/pro/library/farmacology/item102573
  4. ^ Dumayev K.M., Voronina T.A., Smirnov L.D. antioxidants in the prophylaxis and therapy of CNS pathologies. Moscow, 1995
  5. ^ Likhacheva, EB; Sholomov, II (2006). "Clinical and immunological assessment of efficacy of mexidol in the treatment of lumbosacral radiculopathy". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov 106 (10): 52–7. PMID 17117675.